Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Five Below Inc (FIVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Five Below Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Five Below Inc trades at $193.89 (market cap $10.68B). The key difference: Five Below Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| BIO | FIVE | |
|---|---|---|
Market Cap | $8.04B | $10.68B |
Sector | Health | Consumer Staples |
52-Week High | $339.75 | $247.71 |
52-Week Low | $241.71 | $131.94 |
Enterprise Value | $7.85B | $11.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Five Below (FIVE) trades at $191.53, up 1.13% on the day, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 21.13% ROE and 8.67% net margin, supported by revenue growth from $3.6B in 2024 to $3.9B in 2025. Recent milestones include opening its 2,000th store and leadership appointments, driving positive media coverage.
The outlook remains positive with a $252.09 analyst price target implying 31% upside, though risks include volatile cash flows and competitive pressures. Earnings momentum and digital marketing investments position FIVE for growth, but investors should monitor execution against 2026's $5.1B revenue target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
